期刊
JOURNAL OF IMMUNOLOGY
卷 200, 期 10, 页码 3383-3396出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1700064
关键词
-
类别
资金
- Mater Research Institute, the University of Queensland
- Cooperative Research Centre for Biomarker Translation
- Therapeutic Innovation Australia
- National Collaborative Research Infrastructure Strategy program
Anti-CD83 Ab capable of Ab-dependent cellular cytotoxicity can deplete activated CD83(+) human dendritic cells, thereby inhibiting CD4 T cell-mediated acute graft-versus-host disease. As CD83 is also expressed on the surface of activated B lymphocytes, we hypothesized that anti-CD83 would also inhibit B cell responses to stimulation. We found that anti-CD83 inhibited total IgM and IgG production in vitro by allostimulated human PBMC. Also, Ag-specific Ab responses to immunization of SCID mice xeno-grafted with human PBMC were inhibited by anti-CD83 treatment. This inhibition occurred without depletion of all human B cells because anti-CD83 lysed activated CD83(+) B cells by Ab-dependent cellular cytotoxicity and spared resting (CD83(-)) B cells. In cultured human PBMC, anti-CD83 inhibited tetanus toxoid-stimulated B cell proliferation and concomitant dendritic cell-mediated CD4 T cell proliferation and expression of IFN-gamma and IL-17A, with minimal losses of B cells (<20%). In contrast, the anti-CD20 mAb rituximab depleted >80% of B cells but had no effect on CD4 T cell proliferation and cytokine expression. By virtue of the ability of anti-CD83 to selectively deplete activated, but not resting, B cells and dendritic cells, with the latter reducing CD4 T cell responses, anti-CD83 may be clinically useful in autoimmunity and transplantation. Advantages might include inhibited expansion of autoantigen-or alloantigen-specific B cells and CD4 T cells, thus preventing further production of pathogenic Abs and inflammatory cytokines while preserving protective memory and regulatory cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据